Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Fig. 1

Course of liver enzymes GPT (ALT) and GOT (AST) over time. After the first course of pembrolizumab (day 0), a grade 1 transaminitis (CTCAE; version 4.0) reaching values up to 57 U/l (reference up to 35 U/l) was detected. Immunotherapy was paused and MMF switched to CsA. A steady normalization of liver values was obtained after six weeks and therapy with pembrolizumab was continued. Red arrows mark infusion days

Back to article page